Welcome to the Home of Heart Recovery
The FDA has granted Impella® its highest level of approval as a safe and effective therapy for high-risk PCI, cardiogenic shock and right heart failure.
- 1,200+
Peer-reviewed clinical studies have published on Impella, including the PROTECT II randomized controlled trial
- 13
Clinical society guidelines include Impella heart pumps
- 235,000+
Patients have been treated with Impella heart pumps
Influential Trials in High-Risk PCI: Shaping the Future of Ischemic Heart Failure Therapy
Jonathan Hill, MD, discusses influential trials in high-risk PCI that are shaping the future of ischemic heart failure therapy.
Ejection Fraction Improvement Following High-Risk PCI
Impella-supported high-risk PCI leads to a significant 29% relative improvement in LVEF 90 days after the procedure1
For Interventional Cardiologists
Treat high-risk PCI, cardiogenic shock and right heart failure patients
For Cardiac and Vascular Surgeons
Escalate, stabilize and recover native organs with minimally-invasive surgical techniques
For Nurses
Use calculators, watch quick skills videos and learn patient management best practices
For Fellows
Advance your knowledge and develop skills to treat complex PCI patients
For Referring Providers
Are you caring for patients with heart disease? Learn more about how Impella heart pumps work, the benefits of Protected PCI with Impella and explore patient identification resources.
Native Heart and Lung Recovery
Conditions & Therapies
Access education, clinical evidence and practice support for Protected PCI, AMI cardiogenic shock, right heart failure, surgical applications and severe lung failure.
Products & Services
Learn about the latest technology and how that technology may best support your patient.
Education & Resources
Abiomed provides a comprehensive training program for health care providers.
References
- Wollmuth, J., Patel, M. et al. (2022). JSCAI, 100350. https://doi.org/10.1016/j.jscai.2022.100350
NPS-1309